Re: Experimental Tongue Therapy Helps Restore Brain Function
Posted: Wed Dec 12, 2018 4:58 am
Seems Europe is following:
https://heliusmedical.com/index.php/new ... /2018/257-
https://heliusmedical.com/index.php/new ... /2018/257-
Welcome to This is MS, the leading forum for Multiple Sclerosis research and support. Join our friendly community of patients, caregivers, and researchers celebrating over 20 years of delivering hope through knowledge.
https://www.thisisms.com/forum/
This is good news. Thanks for posting.zen2010 wrote:Seems Europe is following:
https://heliusmedical.com/index.php/new ... /2018/257-
NEWTOWN, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, has submitted an application for a CE Mark, the receipt of which will allow the Company to market its Portable Neuromodulation Stimulator (PoNS™) in the European Union.
NEWTOWN, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, entered into an agreement in December 2018 to collaborate with Oregon Health & Science University (OHSU) in Portland, Oregon for launch of its third Clinical Experience Program (CEP) for its Portable Neuromodulation Stimulator (PoNS™).
I'll try to attend.zen2010 wrote: ↑Thu Feb 07, 2019 5:54 am "Management will host a conference call at 4:30 p.m. Eastern Time on March 14 to discuss the results of the quarter and the year. Those who would like to participate may dial 866-393-4306 (734-385-2616 for international callers) and provide access code 8929969. A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://heliusmedical.com/index.php/inv ... ing-events."
Listen to the interview at https://upticknewswire.com/featured-int ... sdaq-hsdt/GlobeNewswire wrote:PHOENIX, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Phoenix, Feb. 11th, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (the “Company”), a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. President and CEO, Phil Deschamps, joined Stock Day host Everett Jolly to discuss their clearance in Canada and share the progress of their expansion into the United States, Europe and Australia.
Jolly began the interview by asking Deschamps to share with listeners what the Company specializes in. Deschamps explained, “We are a company that is dedicated to the treatment of neurological symptoms of disease or trauma. What does that mean? We help to treat the symptoms of things like traumatic brain injury, MS, stroke, and cerebral palsy.”
Deschamps further explained that the Company is in the process of developing a technology called PoNS, which is a non-invasive medical device that, initially, aids in the treatment of traumatic brain injuries. PoNS stands for Portable Neuromodulation Stimulator, and stimulates the patient’s tongue to send impulses to the back of the brain. When paired with exercise, like physical therapy, this combination allows the brain to rehabilitate itself and ease the symptoms caused by disease or trauma.
Jolly then inquired about any recent partnerships made by the Company since their last appearance on the show. Deschamps shared that the Company has developed a clinic system throughout Canada that will allow them to offer both the medical device aspect of the treatment program, as well as the physical therapy side of the treatment. “Every time a patient gets treated, we get a transfer payment into the Company. So, that’s the business model that we are adopting in Canada.”
Deschamps then shared that after clearing Canadian regulations, they are approaching the launch of their clinics and accompanying treatments. In fact, the Company is expecting revenues for the first quarter of 2019. As a formerly pre-revenue company, this is exciting news.
Deschamps explained that the Company’s PoNS device and treatment is currently only licensed in Canada, however they are in the process of expanding into both the United States, Europe and Australia.
To close the interview, Deschamps shared that the Company is eager to expand their non-invasive technology to treat a greater number of conditions, and shared his excitement for the Company’s future.
NEWTOWN, Pa., March 05, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has begun treating patients in Canada with the Company’s Portable Neuromodulation Stimulator (PoNS™) Treatment.
“We are excited to announce the treatment of the first patients in Canada with our PoNS™ device, signifying Helius’ transition to a commercial stage company,” said Philippe Deschamps, Helius’ Chief Executive Officer. “With approximately 400,000 individuals living with chronic balance issues due to a mild to moderate traumatic brain injury (“mTBI”), Canada represents an important market opportunity for Helius. We look forward to providing our innovative PoNS Treatment to all of those suffering from this condition in Canada.”
Helius received authorization from Health Canada to market the PoNS device as an adjunct to physical therapy for chronic balance deficit in patients with mTBI in October 2018. The patients are being treated at one of two neuroplasticity clinics identified by Heuro Canada Inc., which was formed through Helius’ strategic alliance with HealthTech Connex Inc.